Why monotherapy?

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue SUPPL. 1, 2009, Pages

  Williams, Keith J ^a  

^a KW Drug Developments Ltd   (United Kingdom)

Author keywords

Ceftazidime; Meropenem; Neutropenia

Indexed keywords

ANTIINFECTIVE AGENT;

BACTERIAL INFECTION; BLOOD DISEASE; HISTORY; HUMAN; NEUTROPENIA; PYREXIA IDIOPATHICA; REVIEW; UNITED KINGDOM;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; FEVER OF UNKNOWN ORIGIN; HEMATOLOGIC NEOPLASMS; HISTORY, 20TH CENTURY; HUMANS; LONDON; NEUTROPENIA;

EID: 84866442121     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp077     Document Type: Article

References (17)

1. Klastersky J, Meunier-Carpentier F, Prevost JM. Significance of antimicrobial synergism for the outcome of Gram negative sepsis. Am J Med Sci 1977; 273: 157-67.
2. Pizzo PA, Hathorn JW, Hiemenz J et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552-8.
3. de Pauw BE, Kauw F, Muytjens H et al. Ceftazidime versus gentamicin plus cefotaxime in granulocytopenic patients. J Antimicrob Chemother 1983; 12 Suppl A: 93-9.
4. de Pauw B, Williams K, de Neeff J et al. A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother 1985; 28: 824-8.
5. Verhagen CS, de Pauw B, de Witte T et al. Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in neutropenic patients. Antimicrob Agents Chemother 1987; 31: 191-6.
6. Nováková IRO, Donnelly JP, Verhagen CS et al. Teicoplanin as modification of initial empirical therapy in febrile granulocytopenic patients. J Antimicrob Chemother 1990; 25: 985-93.
7. Verhagen C, de Pauw BE, Williams KJ et al. Prospective randomized study of ceftazidime sodium versus ceftazidime arginine in febrile neutropenic patients. Clin Infect Dis 2005; 41: 149-58.
8. Verhagen CAHHVM, de Pauw BE. Treatment of pneumonia in immunocompromised patients. Res Clin Forums 1986; 5: 71-83.
9. de Pauw BE, Rubin RH. The value of randomized clinical trials for daily clinical practice. Transplant Infect Dis 2007; 9: 173-4.
10. Verhagen C, de Pauw BE, Donnelly JP et al. Ceftazidime alone for treating Pseudomonas aeruginosa septicaemia in neutropenia patients. J Infect 1986; 13: 125-13
11. Verhagen C, de Pauw BE, de Witte T et al. Ceftazidime does not enhance cyclosporin-A nephrotoxicity in febrile bone marrow transplantation patients. Blut 1986; 53: 333-9.
12. Feld R, Goodman PJ, Higgins B et al. Prognostic factors predicting for the development of superinfection in febrile neutropenic patients. In: Program and Abstracts of the Thirty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, USA, 1992. p. 393. American Society for Microbiology, Washington, DC, USA.
13. de Pauw BE, Deresinski SC, Feld R et al. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial. Ann Intern Med 1994; 120: 834-44.
14. The Meropenem Study Group of Leuven, London and Nijmegen. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995; 36: 185-200.
15. Feld R, de Pauw B, Berman S et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 2000; 18: 3690-8.
16. Cometta A, Calandra T, Gaya H et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Ann Hematol 1998; 76: 73-80.
17. Paul M, Benuri-Silbiger I, Soares-Weiser K et al. Beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328: 668.